Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Other Non-Current Liabilities (2024)

KalVista Pharmaceuticals' Other Non-Current Liabilities history spans 3 years, with the latest figure at $99.9 million for Q4 2024.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $99.9 million in Q4 2024 year-over-year; TTM through Dec 2024 was $99.9 million, a N/A change, with the full-year FY2014 number at $1.5 million, changed N/A from a year prior.
  • Other Non-Current Liabilities hit $99.9 million in Q4 2024 for KalVista Pharmaceuticals, up from $2.3 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for KALV hit a ceiling of $99.9 million in Q4 2024 and a floor of $99.9 million in Q4 2024.